Energy production
NADH helps carry energy through the chain of reactions that ultimately allows cells to produce usable energy.
Explore the research →REDUCED NAD & CELLULAR REDOX BIOLOGY
NADH
A naturally occurring form of NAD involved in cellular energy, NADH draws interest around fatigue, energy and broader metabolic health.
Redox biologyEnergy metabolismFatigue research
Limited, indication-specific human evidenceSome human studies exist, but NADH is a distinct intervention and evidence for NAD+, NR or NMN should not be transferred to it.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in NADH?
NADH is most often discussed around energy and fatigue because it plays a direct part in the process cells use to turn nutrients into usable energy. That close connection with energy production is what makes it interesting to people looking at tiredness, physical energy and day-to-day performance.
Fatigue
Fatigue is one of the main reasons NADH has been studied as a supplement and remains a common reason for interest today.
Explore the research →Brain & neurological health
NADH has also been explored in some neurological conditions, which has led to wider interest around the brain and cognition.
Explore the research →Cellular balance
NADH works as part of a closely balanced system with NAD+, helping cells move energy and manage chemical reactions efficiently.
Explore the research →THE SCIENCE BIT
The charged partner in an energy-transfer pair.
NADH is the electron-rich form of NAD. It carries electrons from nutrient-processing reactions to machinery that helps make ATP, the cell's usable energy currency.
In mitochondria, NADH donates electrons to respiratory complex I. This normal role explains fatigue-related interest, but an oral NADH product needs evidence beyond the fact that cells use NADH.
See the studies & trials →- NADH
- Carries electrons
- Complex I
- Mitochondrial electron transfer
- ATP
- Usable cellular energy
How this connects to the research
Established biochemistry; supplementation evidence is more limited.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where NADH connects with the body
These are the tissues and biological systems behind the interest in NADH.
- Mitochondria
- Respiratory-chain activity.
- Muscle
- Energy-demanding tissue.
- Brain
- Continuous energy requirements.
The research behind the interest
Energy production
NADH helps carry energy through the chain of reactions that ultimately allows cells to produce usable energy.
That biological role is well established, although taking NADH does not automatically mean someone will feel more energetic or perform better.
Established biology · limited outcome evidenceExplore the studies →Fatigue
Fatigue is one of the main reasons NADH has been studied as a supplement and remains a common reason for interest today.
Small human trials and reviews have produced mixed results, so there is not yet strong evidence for a broad anti-fatigue effect.
Limited human evidenceExplore the studies →Brain & neurological health
NADH has also been explored in some neurological conditions, which has led to wider interest around the brain and cognition.
The evidence is limited to particular settings and does not establish NADH as a general cognitive enhancer.
Early / mixed evidenceExplore the studies →Cellular balance
NADH works as part of a closely balanced system with NAD+, helping cells move energy and manage chemical reactions efficiently.
This is important underlying biology, but the effect of taking NADH depends on how it is absorbed, distributed and used by different tissues.
Strong mechanistic evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableNicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome ↗
86 people with chronic fatigue syndrome; 77 completed the study
OralDaily2 months double-blind treatment within a 3-month study
Most measured clinical variables did not differ significantly between NADH and placebo at the end of treatment.
Some secondary measures changed, including anxiety score and maximum heart rate after exercise, but the trial did not demonstrate broad functional improvement.
Does oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome? ↗
73 people with chronic fatigue syndrome
Oral combinationDaily8 weeks
The combination of CoQ10 and NADH improved some fatigue and biochemical measures versus placebo.
Because NADH was given with CoQ10, the study cannot isolate the effect of NADH alone.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceLimited
2/5 evidence depth
✓
Clinical efficacyEarly
1/5 evidence depth
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
◇
Safety evidenceDeveloping
3/5 evidence depth
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
HOW TO READ THESE SCORESDeveloping preclinical evidence · limited human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
NADH research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Redox biology
RESEARCH AREA 02Energy metabolism
RESEARCH AREA 03Fatigue research
RESEARCH AREA 04Neurological research
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with NADH
NADH is mainly explored for fatigue and mental or physical energy. The biological role is clear, while supplement trials are small, mixed and sometimes combine NADH with another ingredient.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
More capacity when fatigue dominates the day
Interest often centres on tiredness that limits ordinary tasks. People want more usable capacity, rather than merely feeling briefly more alert after taking a product.
- What makes a report informative
- Daily activity and the pattern of fatigue over time.
- What can muddy the picture
- The cause of fatigue and fluctuations in illness strongly affect the experience.
Tolerating activity more comfortably
Some people hope to manage walking, work or exercise with less exhaustion. Accounts are more informative when they describe both the activity and how they felt afterwards.
- What makes a report informative
- Comparable activity and later or next-day fatigue.
- What can muddy the picture
- Pacing, rest and changing workloads can explain improvement.
Understanding NADH plus CoQ10 reports
Combination studies and supplement accounts attract interest in mitochondrial support. This is a different evidence question from whether NADH alone delivers the same benefit.
- What makes a report informative
- The full formulation and the outcome actually measured.
- What can muddy the picture
- A combined-product result cannot isolate NADH or be transferred to NAD+ infusions.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
More energy and less fatigue
Human findings & limits
A randomized chronic-fatigue trial found little difference across most clinical measures, with some secondary signals.
Laboratory & animal context
NADH carries electrons into cellular energy pathways, giving the idea a clear biological basis.
What this means: Biologically plausible but not a dependable broad anti-fatigue effect.
Better exercise tolerance
Human findings & limits
Some secondary exercise measures changed in small studies, but broad functional improvement was not established.
Laboratory & animal context
Cellular redox and ATP production support the hypothesis without proving a performance outcome.
What this means: An uncertain human outcome that needs better, larger trials.
Works better with CoQ10
Human findings & limits
A randomized combination study reported some benefits, but it cannot separate the contribution of NADH from CoQ10.
Laboratory & animal context
Both sit near mitochondrial energy pathways, offering a combination rationale.
What this means: Combination evidence cannot be treated as proof for NADH alone.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
Human NADH studies are indication-specific and often involve chronic-fatigue populations or combination products, so they do not establish a general NADH regimen.
PUBLISHED HUMAN RESEARCH
View source ↗Chronic-fatigue randomized trial ↗
Adults with chronic fatigue syndrome
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Adults with chronic fatigue syndrome. Route: Taken by mouth. The study lasted 2 months double-blind treatment. The figures below describe the research design, not a personal schedule.
| First amount studied | 20 mg/day |
|---|---|
| How often? | Daily |
| How was it given? | Taken by mouth |
| How long? | 2 months double-blind treatment |
See the exact study wording +
Start / initial: 20 mg/day
End / target: 20 mg/day
Frequency: Daily
Route: Oral
Study duration: 2 months double-blind treatment
Source: PMID 20447621 ↗
Disease-specific research protocol; not a general wellness recommendation.
COMMUNITY DISCUSSION
Supplement discussion · limited indication-specific trialsWhat people commonly discuss
STARTING APPROACHES
5–10 mg in the morning is a common lower supplement starting range. Products vary in formulation and absorption.
DURATION / CYCLES
10–20 mg daily for four-to-eight weeks is often discussed when fatigue is the main goal; a small trial used 20 mg daily for two months.
MAINTENANCE DISCUSSION
There is no established long-term maintenance dose or cycling schedule for general energy, cognition or fatigue.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Sixty-day oral human-study example
Human trial · condition-specific, mixed resultsThis chronic-fatigue-syndrome trial used 20 mg daily for the first two months, with assessment at day 60. Most measured outcomes did not show a significant improvement; it does not establish a general wellness regimen.
Form and route: Oral NADH
| Calendar stage | Amount each time |
|---|---|
| Days 1–60 | 20 mg |
Frequency: Every day · 1 entry per scheduled day.
This copy ends at day sixty, matching the reported assessment date.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
The evidence base is small and formulation matters
What the current evidence saysShort oral studies provide some tolerability context but do not define long-term use, higher doses, interactions or outcomes in people with complex illness. Combination trials cannot isolate NADH-specific safety or benefit.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Why this matters
Persistent fatigue can reflect anaemia, sleep problems, thyroid disease, infection, medication effects or other conditions and deserves assessment rather than supplement escalation alone.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
5 sourcesSources used on this profile
Peer-reviewed human trialNicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndromeRevista Clinica Espanola ↗Bibliographic recordNicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndromePubMed ↗Peer-reviewed human trialDoes oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome?Antioxidants & Redox Signaling ↗Bibliographic recordDoes oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome?PubMed ↗Trial registryDoes oral coenzyme Q10 plus NADH supplementation improve fatigue and biochemical parameters in chronic fatigue syndrome?ClinicalTrials.gov ↗
CURRENT STATUS
How to interpret its position today
Limited supplement research
Human trials are small and indication-specific. They do not establish NADH as a general treatment for low energy, cognition or healthy ageing.
Randomized fatigue trial · PubMed ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.